

# Henning Jann

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9141886/henning-jann-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32  
papers

904  
citations

10  
h-index

30  
g-index

36  
ext. papers

1,138  
ext. citations

5.4  
avg, IF

3.69  
L-index

#	Paper	IF	Citations
32	Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. <i>Cancer</i> , <b>2008</b> , 113, 256-65	6.4	335
31	Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. <i>Cancer</i> , <b>2011</b> , 117, 3332-41	6.4	204
30	NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive. <i>Neuroendocrinology</i> , <b>2017</b> , 104, 170-182	5.6	63
29	Malnutrition Predicts Clinical Outcome in Patients with Neuroendocrine Neoplasia. <i>Neuroendocrinology</i> , <b>2017</b> , 104, 11-25	5.6	59
28	Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	54
27	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. <i>Neuroendocrinology</i> , <b>2018</b> , 107, 375-386	5.6	52
26	Placental growth factor supports neuroendocrine tumor growth and predicts disease prognosis in patients. <i>Endocrine-Related Cancer</i> , <b>2013</b> , 20, 305-19	5.7	26
25	Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 1348-1355	3.1	26
24	Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 881-894	8.8	16
23	Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10
22	Identifying Prognostic Factors for Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumours: A Retrospective International Multicentre Cohort Study. <i>Neuroendocrinology</i> , <b>2018</b> , 107, 315-323	5.6	8
21	Management of follow-up of neuroendocrine neoplasias. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 30, 129-40	6.5	6
20	Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3). <i>Cancers</i> , <b>2021</b> , 13,	6.6	6
19	Incidence and prognosis of carcinoid syndrome: hormones or tumour burden?. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e299	21.7	4
18	Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions. <i>Neuroendocrinology</i> , <b>2021</b> , 111, 217-236	5.6	4
17	Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Pancreas</i> , <b>2020</b> , 49, 912-917	2.6	4
16	Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors-Results from an Exploratory Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	4

15	Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations are Elevated in Patients with Neuroendocrine Malignancies. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
14	Asphericity of Somatostatin Receptor Expression in Neuroendocrine Tumors: An Innovative Predictor of Outcome in Everolimus Treatment?. <i>Diagnostics</i> , <b>2020</b> , 10,	3.8	3
13	The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
12	PD-L1 - inhibitors in neuroendocrine neoplasia: Results from a real-life study. <i>Medicine (United States)</i> , <b>2021</b> , 100, e23835	1.8	3
11	Increased Activity of the Immunoregulatory Enzyme Indoleamine-2,3-Dioxygenase with Consecutive Tryptophan Depletion Predicts Death in Patients with Neuroendocrine Neoplasia. <i>Neuroendocrinology</i> , <b>2017</b> , 104, 135-144	5.6	2
10	Serum levels of miR-223 but not miR-21 are decreased in patients with neuroendocrine tumors. <i>PLoS ONE</i> , <b>2020</b> , 15, e0244504	3.7	2
9	Evaluating hepatotoxic effects of chemotherapeutic agents with gadoteric-acid-enhanced magnetic resonance imaging. <i>European Journal of Radiology</i> , <b>2020</b> , 124, 108807	4.7	2
8	Influence of Gender on Therapy and Outcome of Neuroendocrine Tumors of Gastroenteropancreatic Origin: A Single-Center Analysis. <i>Visceral Medicine</i> , <b>2020</b> , 36, 20-27	2.4	1
7	A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report. <i>Molecular and Clinical Oncology</i> , <b>2021</b> , 14, 20	1.6	1
6	The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
5	A case report of an excellent response to interferon- $\gamma$ in a patient with functional metastasized neuroendocrine tumor refractory to other treatments. <i>Medicine (United States)</i> , <b>2020</b> , 99, e20820	1.8	0
4	Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial. <i>BMC Cancer</i> , <b>2021</b> , 21, 1206	4.8	0
3	Everolimus-induced pneumonitis in neuroendocrine neoplasms: correlation of CT findings and clinical signs. <i>Acta Radiologica</i> , <b>2021</b> , 62, 1006-1015	2	0
2	Distribution of gastrointestinal neuroendocrine tumors in Europe: results from a retrospective cross-sectional study.. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2022</b> , 1	4.9	0
1	Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice. <i>Cancers</i> , <b>2022</b> , 14, 2718	6.6	